Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Ginsenoside Rk1 has anti-tumor, and anti-Platelet aggregation activities.
Description | Ginsenoside Rk1 has anti-tumor, and anti-platelet aggregation activities. |
In vitro | Their structure were determined to be 3beta,12beta-dihydroxydammar-20(21),24-diene-3-O-beta-D-glucopyranosyl(1 --> 2)-beta-D-glucopyranoside; 3beta,12beta-dihydroxydammar-20(21),24-diene-3-O-beta-D- glucopyranoside and 3beta,6alpha,12beta-trihydroxydammar-20(21),24-diene-6-O-beta-D-glucopyranoside based on spectroscopic evidences. |
Molecular Weight | 604.869 |
Formula | C36H60O7 |
CAS No. | 364779-14-6 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ginsenoside Rk2 364779-14-6 Angiogenesis Tyrosine Kinase/Adaptors VEGFR Ginsenoside Rk-2 Inhibitor inhibitor inhibit